Charles Fogarty
Pulmonary Disease · Spartanburg, SCNPI 1316919194
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (53.4%), food and beverage and education — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Novo Nordisk AS at 25.6% of the total. Reporting peaked in 2019 at $5,937 and has fallen 93.9% since, to $362 in 2025.
Across 142 payments — averaging $70.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$3K
- AstraZeneca$2K
- Modernatx, Inc.$2K
- Hexal AG$2K
- Electromed, Inc.$807
- Boehringer Ingelheim$447
- plus $1K from 19 others
Across 7,866 payments — averaging $2380.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$6.7M
- Modernatx, Inc.$5.9M
- GSK$1.2M
- Janssen Research & Development, LLC$1.1M
- Emergent Biosolutions Inc.$844K
- Novo Nordisk AS$522K
- plus $2.5M from 25 others
What the payments were for
- Travel & lodging$5,35153%
- Food & beverage$4,62646%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 8 | $2,566 |
| AstraZeneca | 11 | $1,773 |
| Modernatx, Inc. | 6 | $1,738 |
| Hexal AG | 2 | $1,630 |
| Electromed, Inc. | 60 | $807 |
| Boehringer Ingelheim | 10 | $447 |
| Gilead | 12 | $271 |
| Calyxo, Inc. | 2 | $167 |
| Genentech, Inc. | 1 | $129 |
| Sunovion Pharmaceuticals Inc. | 6 | $92 |
| GSK | 4 | $56 |
| Grifols USA, LLC | 3 | $55 |
| Inspire Medical Systems, Inc. | 2 | $39 |
| Resmed Corp | 3 | $37 |
| Philips North America LLC | 2 | $37 |
| Novo Nordisk | 1 | $32 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Sanofi | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $16 |
| Vapotherm Inc | 1 | $16 |
| Pfizer | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEVESPI AEROSPHERE$1,255
- CVAC Aspiration System$144
- XOLAIR$129
- Esbriet$129
- Xofluza$129
- OFEV$125
- TEZSPIRE$124
- BREZTRI$106
How this compares
$10,022 in reported general payments places this provider in the 75th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Spartanburg
- Joseph BosciaSpartanburg$701K
- Farhan SiddiquiSpartanburg$24K
- David ErbSpartanburg$12K
- Abhijit RavalAnderson$2M
- Richard BoganColumbia$1.1M
- Patrick FlumeCharleston$418K
- Sean CallahanGreenville$321K
- Laura HerpelColumbia$254K
- Gerard SilvestriCharleston$254K
- Arun AdlakhaRock Hill$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.